Jco precision oncology.

Dec 1, 2023 · PURPOSE Immune checkpoint inhibitors (ICIs) are used for an increasing number of indications across various tumor types, as well as several tumor-agnostic indications in patients with advanced cancer. Although many patients benefit from ICI therapy, others do not, highlighting a need for better predictive biomarkers. Tumor mutational burden (TMB) reflects the global number of mutations within ...

Jco precision oncology. Things To Know About Jco precision oncology.

DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714Manuscripts Involving Precision Oncology. JCO appreciates the potential value of studies addressing the role of precision oncology in selecting optimal therapy for patients with cancer. Many such studies have already been published, showing the feasibility of performing large scale molecular testing such as Next Generation …Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to …WebAlthough precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to …Web

DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers Harper Hubbeling, MD 1. x. Harper Hubbeling ...WebPURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...May 18, 2021 · As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...

Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ... JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …

This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe. David Cohn. Consulting or Advisory Role: …DOI: 10.1200/PO.20.00417 JCO Precision Oncology no. 5 (2021) 450-454. Published online February 26, 2021. PMID: 34994601. NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets Elke Pfaff, MD. x. Elke Pfaff. Search for articles by this author ...DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ...DOI: 10.1200/PO.21.00047 JCO Precision Oncology no. 5 (2021) 808-816. Published online May 12, 2021. PMID: 34994613. Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs) Kimberly Perez, MD 1, 2. x. Kimberly Perez. Search for articles by this author ...

20 Oct 2022 ... JCO Precision Oncology. Source Reference: opens in a new tab or windowHubbeling H, et al "Outcomes with local therapy and tyrosine kinase ...

By July 20, 2020, 20 patients with TRK fusion–positive lung cancer had been treated. The ORR by investigator assessment among 15 evaluable patients was 73% (95% CI, 45 to 92); one (7%) patient had a complete response, 10 (67%) had a partial response, three (20%) had stable disease, and one (7%) had progressive disease as best response.

DOI: 10.1200/PO.22.00694 JCO Precision Oncology no. 7 (2023) e2200694. Published online September 1, 2023. PMID: 37656949. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Milena Urbini, PhD 1. x. Milena Urbini. Search for articles by this author ...Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ...DOI: 10.1200/PO.20.00495 JCO Precision Oncology no. 5 (2021) 1122-1132. Published online July 9, 2021. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review Kara L. Larson, PhD …WebOncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. DOI: 10.1200/PO.22.00517 JCO Precision Oncology no. 6 (2022) e2200517. Published online November 12, 2022. PMID: 36370464. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer Sarah E. Coughlin, MD 1. x. Sarah E. Coughlin. Search for articles by this author ...This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. Research Funding: Ambry Genetics ...

Jul 9, 2021 · PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ... DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ...When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...DOI: 10.1200/PO.20.00257 JCO Precision Oncology no. 4 (2020) 1393-1402. Published online November 16, 2020. Published online November 16, 2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesJCO Precision Oncology. Published by American Society of Clinical Oncology. Online ISSN: 2473-4284. Top-cited authors. Debyani Chakravarty. Memorial Sloan Kettering …Aug 19, 2021 · DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples

Purpose HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98 ...

Jun 29, 2023 · Cutaneous melanoma (CM) is the fifth most common cancer in the United Sates, with an estimated 99,780 new cases diagnosed in 2022. 1 Prognostic biomarkers aim to identify patients at high or low risk of disease progression to align treatment decisions with the risk of poor outcomes. 2,3 For CM, the most well-established prognostic markers outlined by the American Joint Committee on Cancer ... Aims & Scope of the Journal. JCO Precision Oncology publishes academic articles describing recent essential contributions in the areas of Biological Sciences, General …DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsDOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017DOI: 10.1200/PO.20.00494 JCO Precision Oncology no. 5 (2021) 1325-1338. Published online August 25, 2021. Published online August 25, 2021. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard TherapiesDOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyBy choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your …DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating ...Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer.

Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017

PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ...

DOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …Diagnosis & treatment of ercc3-mutant cancer US20210137850A1. Other Relationship: AnaNeo Therapeutics. Jinru Shia. Consulting or Advisory Role: PAIGE.AI. Zsofia K. Stadler. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Ian F Tannock's Comment1 summarises the experience to date in precision medicine for children with cancer2–4 and its parallel with the adult experience. The …Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer.JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to …WebFeb 6, 2019 · DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019 DOI: 10.1200/PO.22.00197 JCO Precision Oncology no. 6 (2022) e2200197. Published online September 15, 2022. PMID: 36108259. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy ...DOI: 10.1200/PO.20.00060 JCO Precision Oncology no. 4 (2020) 806-817. Published online July 15, 2020. Published online July 15, 2020. Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management

DOI: 10.1200/PO.23.00261 JCO Precision Oncology no. 7 (2023) e2300261. Published online October 12, 2023. PMID: 37824797. Computational Advancements in Cancer Combination Therapy Prediction Victoria L. Flanary, BS 1. x. Victoria L. Flanary. Search for articles by this author ...JCO Precision Oncology, published online May 14, 2018. https://ascopubs.org/doi/full/10.1200/PO.17.00247. Thyroid Cancer. Busaidy NL, Konda B, Wei L, Wirth LJ ...Oct 20, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche Instagram:https://instagram. dgro etfforex trading platforms listlist of stocks in the sandp 500forever 21 legends This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ... smarthealth insurance reviewsbest app for investing in crypto DOI: 10.1200/PO.20.00109 JCO Precision Oncology no. 4 (2020) 898-911. Published online July 28, 2020. PMID: 35050760. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of ...DOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …Web is amazon stock a buy 23 Aug 2021 ... JCO Precision Oncology 2018 :2, 1-13 [Full Text · External Web Site Policy ]. Methods. Wiant K, Geisen E, Creel D, Willis G, Freedman A, de Moor ...Jan 8, 2021 · DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...